Rhabdomyolysis secondary to COVID-19 vaccination: case report

• Autor(a) principal: Oliveira, Andreia
• Data de Publicação: 2023
• Outros Autores: Paraíso, Rita, Lobão, Paola, Guerreiro, Vanessa
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://doi.org/10.32385/rpmgf.v39i1.13545
• topic: Rabdomiólise; Vacina; COVID-19; Rhabdomyolysis; Vaccine; COVID-19

Introduction: Rhabdomyolysis is characterized by skeletal muscle injury. It has been described as a complication of COVID-19 infection, but few cases associated with COVID-19 vaccination have been reported. Case report: After the hospital discharge of an 80-year-old female patient, the family doctor received the admission report for pain and weakness in her lower limbs. Common causes of rhabdomyolysis were excluded; however, it is noteworthy that she had been given the first dose of the vaccine against COVID-19 (Vaxzevria®) one day prior to admission. After management, the symptoms improved, and she was discharged. After a complete evaluation, the patient was found to have vaccine-related rhabdomyolysis, becoming one of the first cases of rhabdomyolysis following an adenoviral vector-based vaccine for COVID-19. Comment: Physicians should be aware of the possibility of COVID-19 vaccine-induced rhabdomyolysis as a potentially serious side-effect in patients with myalgia, weakness, and dark urine. Nonetheless, the benefit-risk assessment shows a favorable balance.